← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › OTHER ANTINEOPLASTIC AGENTS › Hedgehog pathway inhibitors
vismodegib
L01XJ01
Adult Dosing
- Basal cell carcinoma, metastatic or locally advanced: 150 mg orally once daily until disease progression or unacceptable toxicity
Pediatric Dosing
- Safety and efficacy in pediatric patients have not been established
Indications
- Treatment of metastatic basal cell carcinoma
- Treatment of locally advanced basal cell carcinoma in patients who are not candidates for surgery or radiation
Mechanism of Action
- Hedgehog pathway inhibitor that binds to and inhibits Smoothened (SMO), preventing downstream signaling and transcription of hedgehog target genes
Contraindications
- Pregnancy
- Breastfeeding
- Known hypersensitivity to vismodegib or its excipients
Adverse Reactions
- Muscle spasms
- Alopecia
- Dysgeusia
- Weight loss
- Fatigue
- Nausea
- Diarrhea
- Amenorrhea
- Elevated blood urea nitrogen and creatinine
Drug Interactions
- No formal clinical drug-drug interaction studies have been conducted
- In vitro studies suggest vismodegib is not an inhibitor or inducer of major CYP450 enzymes
Curated Content: Needs Vetting Before Put to Clinical Use